Loading stock research
Loading stock research…
No token price observed
Observation time unavailableUnavailable
Underlying share reference$239.85(Jupiter stock data)
A reference quote for JAZZ, not a price you can trade the token at.
Updated · Source: Jupiter stock data
Buy from your own wallet on Solana mainnet. You review and sign every transaction.
Checking whether mainnet purchases are available…
You sign in your own wallet. Ovelo never holds your keys or funds.
Daily closes of JAZZ, the underlying share. A token’s rights, price and liquidity can differ from the share.
Research observed · Source: Yahoo Finance, Wikipedia (CC BY-SA)
What you would hold, where it trades and where these numbers come from.
Observation time unavailableUnavailable
The company behind JAZZ.
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
Observed · Source: Company profile
Momentum from daily closes of the underlying share.
Computed from daily closes of the underlying share, not the token. Not a recommendation.
Close of · Source: Yahoo Finance daily closesStale
Reported financials. They describe the company, not the token’s market value.
| Item | Period end | Value |
|---|---|---|
| Revenue (annual) | 31 Dec 2025 | $4.27B |
| Revenue (annual) | 31 Dec 2024 | $4.07B |
| Revenue (annual) | 31 Dec 2023 | $3.83B |
| Revenue (annual) | 31 Dec 2022 | $3.66B |
| Net income (annual) | 31 Dec 2025 | −$356.15M |
| Net income (annual) | 31 Dec 2024 | $560.12M |
| Net income (annual) | 31 Dec 2023 | $414.83M |
| Net income (annual) | 31 Dec 2022 | −$224.06M |
| Diluted EPS (annual) | 31 Dec 2025 | −5.84 USD/share |
| Diluted EPS (annual) | 31 Dec 2024 | 8.65 USD/share |
| Diluted EPS (annual) | 31 Dec 2023 | 6.10 USD/share |
| Diluted EPS (annual) | 31 Dec 2022 | −3.58 USD/share |
| Total assets (annual) | 31 Dec 2025 | $11.66B |
| Total assets (annual) | 31 Dec 2024 | $12.01B |
| Total assets (annual) | 31 Dec 2023 | $11.39B |
| Total assets (annual) | 31 Dec 2022 | $10.84B |
| Total debt (annual) | 31 Dec 2025 | $5.42B |
| Total debt (annual) | 31 Dec 2024 | $6.16B |
| Total debt (annual) | 31 Dec 2023 | $5.79B |
| Total debt (annual) | 31 Dec 2022 | $5.81B |
| Operating cash flow (annual) | 31 Dec 2025 | $1.36B |
| Operating cash flow (annual) | 31 Dec 2024 | $1.40B |
| Operating cash flow (annual) | 31 Dec 2023 | $1.09B |
| Operating cash flow (annual) | 31 Dec 2022 | $1.27B |
| Free cash flow (annual) | 31 Dec 2025 | $1.15B |
| Free cash flow (annual) | 31 Dec 2024 | $1.35B |
| Free cash flow (annual) | 31 Dec 2023 | $1.05B |
| Free cash flow (annual) | 31 Dec 2022 | $773.78M |
| Revenue (quarterly) | 30 Sept 2026 | $1.24B |
| Revenue (quarterly) | 30 Jun 2026 | $1.21B |
| Revenue (quarterly) | 31 Mar 2026 | $1.07B |
| Revenue (quarterly) | 31 Dec 2025 | $1.20B |
| Revenue (quarterly) | 30 Sept 2025 | $1.13B |
| Net income (quarterly) | 30 Sept 2026 | −$483.40M |
| Net income (quarterly) | 30 Jun 2026 | $192.80M |
| Net income (quarterly) | 31 Mar 2026 | $293.10M |
| Net income (quarterly) | 31 Dec 2025 | $203.45M |
| Net income (quarterly) | 30 Sept 2025 | $251.40M |
| Diluted EPS (quarterly) | 30 Sept 2026 | −7.48 USD/share |
| Diluted EPS (quarterly) | 30 Jun 2026 | 2.78 USD/share |
| Diluted EPS (quarterly) | 31 Mar 2026 | 4.43 USD/share |
| Diluted EPS (quarterly) | 31 Dec 2025 | 3.21 USD/share |
| Diluted EPS (quarterly) | 30 Sept 2025 | 4.08 USD/share |
Reported dividends, splits and filings, each linked to its source.
No dividends, splits or filings were found.
Recent headlines about the company.